Gut microbiota in chronic kidney disease
- PMID: 27553986
- DOI: 10.1016/j.nefro.2016.05.008
Gut microbiota in chronic kidney disease
Abstract
The intestinal microflora maintains a symbiotic relationship with the host under normal conditions, but its imbalance has recently been associated with several diseases. In chronic kidney disease (CKD), dysbiotic intestinal microflora has been reported with an increase in pathogenic flora compared to symbiotic flora. An enhanced permeability of the intestinal barrier, allowing the passage of endotoxins and other bacterial products to the blood, has also been shown in CKD. By fermenting undigested products that reach the colon, the intestinal microflora produce indoles, phenols and amines, among others, that are absorbed by the host, accumulate in CKD and have harmful effects on the body. These gut-derived uraemic toxins and the increased permeability of the intestinal barrier in CKD have been associated with increased inflammation and oxidative stress and have been involved in various CKD-related complications, including cardiovascular disease, anaemia, mineral metabolism disorders or the progression of CKD. The use of prebiotics, probiotics or synbiotics, among other approaches, could improve the dysbiosis and/or the increased permeability of the intestinal barrier in CKD. This article describes the situation of the intestinal microflora in CKD, the alteration of the intestinal barrier and its clinical consequences, the harmful effects of intestinal flora-derived uraemic toxins, and possible therapeutic options to improve this dysbiosis and reduce CKD-related complications.
Keywords: Chronic kidney disease; Disbiosis; Dysbiosis; Enfermedad renal crónica; Gut microbiota; Inflamación; Inflammation; Microbiota intestinal; Toxinas urémicas; Uraemic toxins.
Copyright © 2016 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.
Similar articles
-
[Pathomechanism and treatment of gut microbiota dysbiosis in chronic kidney disease and interventional effects of Chinese herbal medicine].Zhongguo Zhong Yao Za Zhi. 2017 Jul;42(13):2425-2432. doi: 10.19540/j.cnki.cjcmm.20170609.014. Zhongguo Zhong Yao Za Zhi. 2017. PMID: 28840678 Review. Chinese.
-
The Impact of CKD on Uremic Toxins and Gut Microbiota.Toxins (Basel). 2021 Mar 31;13(4):252. doi: 10.3390/toxins13040252. Toxins (Basel). 2021. PMID: 33807343 Free PMC article. Review.
-
Microbiota issue in CKD: how promising are gut-targeted approaches?J Nephrol. 2019 Feb;32(1):27-37. doi: 10.1007/s40620-018-0516-0. Epub 2018 Aug 1. J Nephrol. 2019. PMID: 30069677 Review.
-
The clinical impact of gut microbiota in chronic kidney disease.Korean J Intern Med. 2020 Nov;35(6):1305-1316. doi: 10.3904/kjim.2020.411. Epub 2020 Sep 29. Korean J Intern Med. 2020. PMID: 32872729 Free PMC article. Review.
-
The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.Pharmacol Res. 2019 Mar;141:366-377. doi: 10.1016/j.phrs.2019.01.019. Epub 2019 Jan 10. Pharmacol Res. 2019. PMID: 30639376 Review.
Cited by
-
Enzobiotics-A Novel Therapy for the Elimination of Uremic Toxins in Patients with CKD (EETOX Study): A Multicenter Double-Blind Randomized Controlled Trial.Nutrients. 2022 Sep 15;14(18):3804. doi: 10.3390/nu14183804. Nutrients. 2022. PMID: 36145188 Free PMC article. Clinical Trial.
-
Effects of fecal microbiota transplantation for recurrent Clostridium difficile infection in children on kidney replacement therapy: a pilot study.Pediatr Nephrol. 2024 Apr;39(4):1201-1212. doi: 10.1007/s00467-023-06168-6. Epub 2023 Sep 30. Pediatr Nephrol. 2024. PMID: 37775582
-
The Regulation of Host Intestinal Microbiota by Polyphenols in the Development and Prevention of Chronic Kidney Disease.Front Immunol. 2020 Jan 8;10:2981. doi: 10.3389/fimmu.2019.02981. eCollection 2019. Front Immunol. 2020. PMID: 31969882 Free PMC article. Review.
-
The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease.Int J Mol Sci. 2021 Sep 6;22(17):9641. doi: 10.3390/ijms22179641. Int J Mol Sci. 2021. PMID: 34502562 Free PMC article. Review.
-
Dynamic gut microbiome-metabolome in cationic bovine serum albumin induced experimental immune-complex glomerulonephritis and effect of losartan and mycophenolate mofetil on microbiota modulation.J Pharm Anal. 2024 Apr;14(4):100931. doi: 10.1016/j.jpha.2023.12.021. Epub 2023 Dec 30. J Pharm Anal. 2024. PMID: 38655401 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical